Loading…

IL-17A Is Elevated in End-Stage Chronic Obstructive Pulmonary Disease and Contributes to Cigarette Smoke-induced Lymphoid Neogenesis

End-stage chronic obstructive pulmonary disease (COPD) is associated with an accumulation of pulmonary lymphoid follicles. IL-17A is implicated in COPD and pulmonary lymphoid neogenesis in response to microbial stimuli. We hypothesized that IL-17A is increased in peripheral lung tissue during end-st...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2015-06, Vol.191 (11), p.1232-1241
Main Authors: Roos, Abraham B, Sandén, Caroline, Mori, Michiko, Bjermer, Leif, Stampfli, Martin R, Erjefält, Jonas S
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c446t-4fde67e20b766f127971eb2a0adda11aa97745b9d83e8e8ed90784d8ce018adf3
cites cdi_FETCH-LOGICAL-c446t-4fde67e20b766f127971eb2a0adda11aa97745b9d83e8e8ed90784d8ce018adf3
container_end_page 1241
container_issue 11
container_start_page 1232
container_title American journal of respiratory and critical care medicine
container_volume 191
creator Roos, Abraham B
Sandén, Caroline
Mori, Michiko
Bjermer, Leif
Stampfli, Martin R
Erjefält, Jonas S
description End-stage chronic obstructive pulmonary disease (COPD) is associated with an accumulation of pulmonary lymphoid follicles. IL-17A is implicated in COPD and pulmonary lymphoid neogenesis in response to microbial stimuli. We hypothesized that IL-17A is increased in peripheral lung tissue during end-stage COPD and also directly contributes to cigarette smoke-induced lymphoid neogenesis. To characterize the tissue expression and functional role of IL-17A in end-stage COPD. Automated immune detection of IL-17A and IL-17F was performed in lung tissue specimens collected from patients with Global Initiative for Chronic Obstructive Lung Disease stage I-IV COPD, and smoking and never-smoking control subjects. In parallel, Il17a(-/-) mice and wild-type control animals were exposed to cigarette smoke for 24 weeks, and pulmonary lymphoid neogenesis was assessed. Tissue expression of IL-17A and IL-17F was increased in COPD and correlated with lung function decline. IL-17A was significantly elevated in severe to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease III/IV) compared with both smokers and never-smokers without COPD. Although CD3(+) T cells expressed IL-17A in very severe COPD, most IL-17A(+) cells were identified as tryptase-positive mast cells. Attenuated lymphoid neogenesis and reduced expression of the B-cell attracting chemokine C-X-C motif ligand (CXCL) 12 was observed in cigarette smoke-exposed Il17a(-/-) mice. CXCL12 was also highly expressed in lymphoid follicles in COPD lungs, and the pulmonary expression was significantly elevated in end-stage COPD. IL-17A in the peripheral lung of patients with severe to very severe COPD may contribute to disease progression and development of lymphoid follicles via activation of CXCL12.
doi_str_mv 10.1164/rccm.201410-1861oc
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1685750085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1685750085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-4fde67e20b766f127971eb2a0adda11aa97745b9d83e8e8ed90784d8ce018adf3</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhi0Eoh_wBzggS1y4pPUkTuwcq7AtK61YpILELXLsydYlsRfbqdR7f3i92sIBzWHm8Myr0TyEfAB2AdDwy6D1fFEy4MAKkA14_YqcQl3VBW8Fe51nJqqC8_bXCTmL8Z4xKCWwt-SkrCXnDchT8rTeFCCu6DrS1YQPKqGh1tGVM8VtUjuk3V3wzmq6HWIKi072Aen3ZZq9U-GRfrERVUSqnKGddynYYUkYafK0szsVMCWkt7P_jYV1ZtE5ffM47--8NfQb-h06jDa-I29GNUV8_9LPyc_r1Y_ua7HZ3qy7q02h87Wp4KPBRmDJBtE0I5SiFYBDqZgyRgEo1QrB66E1skKZy7RMSG6kRgZSmbE6J5-Pufvg_ywYUz_bqHGalEO_xB4aWYuaMVln9NN_6L1fgsvXHaimankjZabKI6WDjzHg2O-DnfNjemD9wVF_cNQfHfUHR9suL318iV6GGc2_lb9SqmdUd46-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1686394688</pqid></control><display><type>article</type><title>IL-17A Is Elevated in End-Stage Chronic Obstructive Pulmonary Disease and Contributes to Cigarette Smoke-induced Lymphoid Neogenesis</title><source>Freely Accessible Science Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Roos, Abraham B ; Sandén, Caroline ; Mori, Michiko ; Bjermer, Leif ; Stampfli, Martin R ; Erjefält, Jonas S</creator><creatorcontrib>Roos, Abraham B ; Sandén, Caroline ; Mori, Michiko ; Bjermer, Leif ; Stampfli, Martin R ; Erjefält, Jonas S</creatorcontrib><description>End-stage chronic obstructive pulmonary disease (COPD) is associated with an accumulation of pulmonary lymphoid follicles. IL-17A is implicated in COPD and pulmonary lymphoid neogenesis in response to microbial stimuli. We hypothesized that IL-17A is increased in peripheral lung tissue during end-stage COPD and also directly contributes to cigarette smoke-induced lymphoid neogenesis. To characterize the tissue expression and functional role of IL-17A in end-stage COPD. Automated immune detection of IL-17A and IL-17F was performed in lung tissue specimens collected from patients with Global Initiative for Chronic Obstructive Lung Disease stage I-IV COPD, and smoking and never-smoking control subjects. In parallel, Il17a(-/-) mice and wild-type control animals were exposed to cigarette smoke for 24 weeks, and pulmonary lymphoid neogenesis was assessed. Tissue expression of IL-17A and IL-17F was increased in COPD and correlated with lung function decline. IL-17A was significantly elevated in severe to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease III/IV) compared with both smokers and never-smokers without COPD. Although CD3(+) T cells expressed IL-17A in very severe COPD, most IL-17A(+) cells were identified as tryptase-positive mast cells. Attenuated lymphoid neogenesis and reduced expression of the B-cell attracting chemokine C-X-C motif ligand (CXCL) 12 was observed in cigarette smoke-exposed Il17a(-/-) mice. CXCL12 was also highly expressed in lymphoid follicles in COPD lungs, and the pulmonary expression was significantly elevated in end-stage COPD. IL-17A in the peripheral lung of patients with severe to very severe COPD may contribute to disease progression and development of lymphoid follicles via activation of CXCL12.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><identifier>DOI: 10.1164/rccm.201410-1861oc</identifier><identifier>PMID: 25844618</identifier><language>eng</language><publisher>United States: American Thoracic Society</publisher><subject>Aged ; Animals ; Chemokine CXCL12 - metabolism ; Disease Models, Animal ; Disease Progression ; Female ; Humans ; Interleukin-17 - immunology ; Lung - pathology ; Lymphoid Tissue - metabolism ; Lymphoid Tissue - pathology ; Male ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Pulmonary Disease, Chronic Obstructive - immunology ; Pulmonary Disease, Chronic Obstructive - pathology ; Smoking - adverse effects</subject><ispartof>American journal of respiratory and critical care medicine, 2015-06, Vol.191 (11), p.1232-1241</ispartof><rights>Copyright American Thoracic Society Jun 1, 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-4fde67e20b766f127971eb2a0adda11aa97745b9d83e8e8ed90784d8ce018adf3</citedby><cites>FETCH-LOGICAL-c446t-4fde67e20b766f127971eb2a0adda11aa97745b9d83e8e8ed90784d8ce018adf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25844618$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roos, Abraham B</creatorcontrib><creatorcontrib>Sandén, Caroline</creatorcontrib><creatorcontrib>Mori, Michiko</creatorcontrib><creatorcontrib>Bjermer, Leif</creatorcontrib><creatorcontrib>Stampfli, Martin R</creatorcontrib><creatorcontrib>Erjefält, Jonas S</creatorcontrib><title>IL-17A Is Elevated in End-Stage Chronic Obstructive Pulmonary Disease and Contributes to Cigarette Smoke-induced Lymphoid Neogenesis</title><title>American journal of respiratory and critical care medicine</title><addtitle>Am J Respir Crit Care Med</addtitle><description>End-stage chronic obstructive pulmonary disease (COPD) is associated with an accumulation of pulmonary lymphoid follicles. IL-17A is implicated in COPD and pulmonary lymphoid neogenesis in response to microbial stimuli. We hypothesized that IL-17A is increased in peripheral lung tissue during end-stage COPD and also directly contributes to cigarette smoke-induced lymphoid neogenesis. To characterize the tissue expression and functional role of IL-17A in end-stage COPD. Automated immune detection of IL-17A and IL-17F was performed in lung tissue specimens collected from patients with Global Initiative for Chronic Obstructive Lung Disease stage I-IV COPD, and smoking and never-smoking control subjects. In parallel, Il17a(-/-) mice and wild-type control animals were exposed to cigarette smoke for 24 weeks, and pulmonary lymphoid neogenesis was assessed. Tissue expression of IL-17A and IL-17F was increased in COPD and correlated with lung function decline. IL-17A was significantly elevated in severe to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease III/IV) compared with both smokers and never-smokers without COPD. Although CD3(+) T cells expressed IL-17A in very severe COPD, most IL-17A(+) cells were identified as tryptase-positive mast cells. Attenuated lymphoid neogenesis and reduced expression of the B-cell attracting chemokine C-X-C motif ligand (CXCL) 12 was observed in cigarette smoke-exposed Il17a(-/-) mice. CXCL12 was also highly expressed in lymphoid follicles in COPD lungs, and the pulmonary expression was significantly elevated in end-stage COPD. IL-17A in the peripheral lung of patients with severe to very severe COPD may contribute to disease progression and development of lymphoid follicles via activation of CXCL12.</description><subject>Aged</subject><subject>Animals</subject><subject>Chemokine CXCL12 - metabolism</subject><subject>Disease Models, Animal</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Interleukin-17 - immunology</subject><subject>Lung - pathology</subject><subject>Lymphoid Tissue - metabolism</subject><subject>Lymphoid Tissue - pathology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Middle Aged</subject><subject>Pulmonary Disease, Chronic Obstructive - immunology</subject><subject>Pulmonary Disease, Chronic Obstructive - pathology</subject><subject>Smoking - adverse effects</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpdkU1v1DAQhi0Eoh_wBzggS1y4pPUkTuwcq7AtK61YpILELXLsydYlsRfbqdR7f3i92sIBzWHm8Myr0TyEfAB2AdDwy6D1fFEy4MAKkA14_YqcQl3VBW8Fe51nJqqC8_bXCTmL8Z4xKCWwt-SkrCXnDchT8rTeFCCu6DrS1YQPKqGh1tGVM8VtUjuk3V3wzmq6HWIKi072Aen3ZZq9U-GRfrERVUSqnKGddynYYUkYafK0szsVMCWkt7P_jYV1ZtE5ffM47--8NfQb-h06jDa-I29GNUV8_9LPyc_r1Y_ua7HZ3qy7q02h87Wp4KPBRmDJBtE0I5SiFYBDqZgyRgEo1QrB66E1skKZy7RMSG6kRgZSmbE6J5-Pufvg_ywYUz_bqHGalEO_xB4aWYuaMVln9NN_6L1fgsvXHaimankjZabKI6WDjzHg2O-DnfNjemD9wVF_cNQfHfUHR9suL318iV6GGc2_lb9SqmdUd46-</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Roos, Abraham B</creator><creator>Sandén, Caroline</creator><creator>Mori, Michiko</creator><creator>Bjermer, Leif</creator><creator>Stampfli, Martin R</creator><creator>Erjefält, Jonas S</creator><general>American Thoracic Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20150601</creationdate><title>IL-17A Is Elevated in End-Stage Chronic Obstructive Pulmonary Disease and Contributes to Cigarette Smoke-induced Lymphoid Neogenesis</title><author>Roos, Abraham B ; Sandén, Caroline ; Mori, Michiko ; Bjermer, Leif ; Stampfli, Martin R ; Erjefält, Jonas S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-4fde67e20b766f127971eb2a0adda11aa97745b9d83e8e8ed90784d8ce018adf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Animals</topic><topic>Chemokine CXCL12 - metabolism</topic><topic>Disease Models, Animal</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Interleukin-17 - immunology</topic><topic>Lung - pathology</topic><topic>Lymphoid Tissue - metabolism</topic><topic>Lymphoid Tissue - pathology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Middle Aged</topic><topic>Pulmonary Disease, Chronic Obstructive - immunology</topic><topic>Pulmonary Disease, Chronic Obstructive - pathology</topic><topic>Smoking - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roos, Abraham B</creatorcontrib><creatorcontrib>Sandén, Caroline</creatorcontrib><creatorcontrib>Mori, Michiko</creatorcontrib><creatorcontrib>Bjermer, Leif</creatorcontrib><creatorcontrib>Stampfli, Martin R</creatorcontrib><creatorcontrib>Erjefält, Jonas S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roos, Abraham B</au><au>Sandén, Caroline</au><au>Mori, Michiko</au><au>Bjermer, Leif</au><au>Stampfli, Martin R</au><au>Erjefält, Jonas S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IL-17A Is Elevated in End-Stage Chronic Obstructive Pulmonary Disease and Contributes to Cigarette Smoke-induced Lymphoid Neogenesis</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><addtitle>Am J Respir Crit Care Med</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>191</volume><issue>11</issue><spage>1232</spage><epage>1241</epage><pages>1232-1241</pages><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>End-stage chronic obstructive pulmonary disease (COPD) is associated with an accumulation of pulmonary lymphoid follicles. IL-17A is implicated in COPD and pulmonary lymphoid neogenesis in response to microbial stimuli. We hypothesized that IL-17A is increased in peripheral lung tissue during end-stage COPD and also directly contributes to cigarette smoke-induced lymphoid neogenesis. To characterize the tissue expression and functional role of IL-17A in end-stage COPD. Automated immune detection of IL-17A and IL-17F was performed in lung tissue specimens collected from patients with Global Initiative for Chronic Obstructive Lung Disease stage I-IV COPD, and smoking and never-smoking control subjects. In parallel, Il17a(-/-) mice and wild-type control animals were exposed to cigarette smoke for 24 weeks, and pulmonary lymphoid neogenesis was assessed. Tissue expression of IL-17A and IL-17F was increased in COPD and correlated with lung function decline. IL-17A was significantly elevated in severe to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease III/IV) compared with both smokers and never-smokers without COPD. Although CD3(+) T cells expressed IL-17A in very severe COPD, most IL-17A(+) cells were identified as tryptase-positive mast cells. Attenuated lymphoid neogenesis and reduced expression of the B-cell attracting chemokine C-X-C motif ligand (CXCL) 12 was observed in cigarette smoke-exposed Il17a(-/-) mice. CXCL12 was also highly expressed in lymphoid follicles in COPD lungs, and the pulmonary expression was significantly elevated in end-stage COPD. IL-17A in the peripheral lung of patients with severe to very severe COPD may contribute to disease progression and development of lymphoid follicles via activation of CXCL12.</abstract><cop>United States</cop><pub>American Thoracic Society</pub><pmid>25844618</pmid><doi>10.1164/rccm.201410-1861oc</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1073-449X
ispartof American journal of respiratory and critical care medicine, 2015-06, Vol.191 (11), p.1232-1241
issn 1073-449X
1535-4970
language eng
recordid cdi_proquest_miscellaneous_1685750085
source Freely Accessible Science Journals; EZB-FREE-00999 freely available EZB journals
subjects Aged
Animals
Chemokine CXCL12 - metabolism
Disease Models, Animal
Disease Progression
Female
Humans
Interleukin-17 - immunology
Lung - pathology
Lymphoid Tissue - metabolism
Lymphoid Tissue - pathology
Male
Mice
Mice, Inbred C57BL
Middle Aged
Pulmonary Disease, Chronic Obstructive - immunology
Pulmonary Disease, Chronic Obstructive - pathology
Smoking - adverse effects
title IL-17A Is Elevated in End-Stage Chronic Obstructive Pulmonary Disease and Contributes to Cigarette Smoke-induced Lymphoid Neogenesis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A46%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IL-17A%20Is%20Elevated%20in%20End-Stage%20Chronic%20Obstructive%20Pulmonary%20Disease%20and%20Contributes%20to%20Cigarette%20Smoke-induced%20Lymphoid%20Neogenesis&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Roos,%20Abraham%20B&rft.date=2015-06-01&rft.volume=191&rft.issue=11&rft.spage=1232&rft.epage=1241&rft.pages=1232-1241&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/10.1164/rccm.201410-1861oc&rft_dat=%3Cproquest_cross%3E1685750085%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-4fde67e20b766f127971eb2a0adda11aa97745b9d83e8e8ed90784d8ce018adf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1686394688&rft_id=info:pmid/25844618&rfr_iscdi=true